AdAlta Limited (ASX: 1AD), the biotechnology Company advancing its lead i-body candidate towards clinical development, today announced that CEO, Samantha Cobb would present at the Biotech Showcase™, to be held between 8–10 January, during the most important week in the annual meeting calendar for healthcare companies.
Date: Wednesday 10 January
Time: The presentation will occur at 9:30 am PST
Room: Franciscan A, Level Ballroom Level
Venue: Hilton Hotel Union Square, 333 O’Farrell Street, San Francisco
A copy of the presentation is available here.
CEO, Sam Cobb, said, “2018 is going to be a big year for AdAlta as we move our lead program AD-114 into the clinic for the treatment of orphan disease, Idiopathic Pulmonary Fibrosis. AdAlta represents a strong investment opportunity for investors at this stage, given the precedent for deals in the fibrosis area. It is an excellent time for us to present in front of the US audience.”
Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.
Sara Demy-Colton, CEO of Demy-Colton, said: “We are delighted that AdAlta will be presenting at the Biotech Showcase this year. Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. This year again we are thrilled to be hosting what we believe will be the great business development opportunity of 2018.”
Any investors that wish to meet with Sam Cobb during the conference can make contact through the partnering system, or via the contact details provided below.
Sam Cobb, CEO
Tel: +61 (0)3 9479 5159
Follow AdAlta on Twitter: @AdAltaCEO | follow Biotech Showcase on Twitter: @EBDGroup and @Demy_Colton – #BiotechShowcase.